We previously created a knock-in mutant mouse harboring a dominantly negative mutant
thyroid hormone receptor beta (TRbeta(PV/PV) mouse) that spontaneously develops a
follicular thyroid carcinoma similar to human
thyroid cancer. We found that
beta-catenin, which plays a critical role in
oncogenesis, was highly elevated in thyroid
tumors of TRbeta(PV/PV) mice. We sought to understand the molecular basis underlying aberrant accumulation of
beta-catenin by mutations of TRbeta in vivo. Cell-based studies showed that
thyroid hormone (T3) induced the degradation of
beta-catenin in cells expressing TRbeta via proteasomal pathways. In contrast, no T3-induced degradation occurred in cells expressing the mutant receptor (TRbetaPV). In vitro binding studies and cell-based analyses revealed that
beta-catenin physically associated with unliganded TRbeta or TRbetaPV. However, in the presence of T3,
beta-catenin was dissociated from TRbeta-
beta-catenin complexes but not from TRbetaPV-
beta-catenin complexes.
beta-Catenin signaling was repressed by T3 in TRbeta-expressing cells through decreasing
beta-catenin-mediated transcription activity and target gene expression, whereas sustained
beta-catenin signaling was observed in TRbetaPV-expressing cells. The stabilization of
beta-catenin, via association with a mutated TRbeta, represents a novel activating mechanism of the oncogenic
protein beta-catenin that could contribute to thyroid
carcinogenesis in TRbeta(PV/PV) mice.